For over a decade, exon-skipping drugs dominated conversations around the Duchenne Muscular Dystrophy Treatment Market. But the Duchenne Muscular Dystrophy Market has moved well past that single mechanism, with gene therapy, pipeline innovation, and evolving safety data reshaping how clinicians and families think about care. Here's a look at where the science, the business, and the unmet needs...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek